Phenomenex said that its spin-off firm, Neoteryx, has released its Mitra Microsampling Device. Intended as an alternative to conventional blood draws, the device, according to the company consistently collects 10 µL of fluid while eliminating the volumetric blood hematocrit bias typically associated with the dried blood spotting technique.
OncoPlex Dx has added a quantitative androgen receptor assay to its mass spec-based Breast Cancer Proteomic Panel.